The aim of the present study was to assess the effects of angiotensin II receptor blocker (ARB) on coronary plaque progression in patients with acute myocardial infarction (AMI) who received an angiotensin-converting enzyme inhibitor (ACEI).
atients with acute myocardial infarction (AMI) have a greatly increased risk of subsequent fatal and non-fatal cardiovascular events. Pharmacotherapy is widely accepted to be effective for secondary prevention, but a considerable number of patients still have cardiovascular events. Many randomized, placebo-controlled trials have demonstrated that inhibition of the renin-angiotensin-aldosterone system (RAS) by treatment with an angiotensin-converting enzyme inhibitor (ACEI) reduces the risk of death as well as of major non-fatal cardiovascular events after AMI, and prevents events related to ischemia and atherosclerosis, regardless of blood pressure. 1, 2 Angiotensin II receptor blockers (ARBs) are thought to act through angiotensin type 1 receptors without affecting the breakdown of bradykinin, thereby avoiding the undesirable side-effects of ACEIs. ARBs may offer thus an alternative approach to RAS inhibition. Recent trials have demonstrated that ARBs are as effective as ACEIs in improving survival and reducing cardiovascular morbidity in patients with congestive heart failure. 3-5 These findings suggest that combined treatment with an ACEI and ARB might more systematically inhibit RAS than ACEI monotherapy. The combined effects of these drugs might thus have higher anti-atherosclerotic efficacy. Whether a combination of these drugs has a favorable effect on coronary atherosclerosis in patients with AMI after successful coronary revascularization, however, remains to be Effect of ARB on Coronary Atherosclerosis determined.
Recently, serial assessments of plaque burden on intravascular ultrasound (IVUS) have emerged as a new surrogate marker for the progression of coronary atherosclerosis. This imaging modality is considered accurate and reliable for evaluating the effects of therapies on the progression of coronary atherosclerosis. [6] [7] [8] The Captopril combined with Valsartan in Acute myocardial infarction Study (CVAS) compared the combination of an ACEI (captopril) and ARB (valsartan) with an ACEI alone in patients with AMI. The present serial IVUS study compared the effects of these 2 treatments on non-culprit intermediate coronary atherosclerosis. It was designed to test the hypothesis that the addition of an ARB to an ACEI more effectively retards the progression of coronary atherosclerosis than lowering blood pressure alone.
Methods

Study Design
The CVAS was a prospective, open-label, randomized, singlecenter study. This study was approved by Yokohama City University institutional review boards including members from outside the hospital, and conducted in accordance with the guidelines of the ethics committee of Yokohama City University. All patients provided written informed consent for the medication regimens and the baseline and follow-up IVUS. Men and women with AMI who were aged 20-79 years and who were admitted within 24 h from onset symptom were eligible. The diagnosis of AMI was based on episodes of chest pain persisting for at least 30 min, electrocardiographic evidence of STsegment elevation in at least 2 contiguous leads, and an elevation of creatinine phosphokinase to >2-fold the upper limit of normal. All patients had successfully undergone percutaneous coronary intervention (PCI) of culprit lesions under IVUS guidance. At study entry, patients were required to have a systolic blood pressure >100 mmHg and a serum creatinine concentration <1.2 mg/dl. Patients were allowed to have received an ACEI or ARB up to 12 h before study entry. Patients were excluded if they had a history of intolerance or contraindication to ACEIs or ARBs, clinically significant valvular disease, another disease expected to seriously compromise life expectancy, or cardiogenic shock. Patients who did not give written informed consent were also excluded.
Enrolled patients were randomly assigned to receive either captopril monotherapy or captopril plus valsartan according to the sealed envelope method. After PCI, the physicians in the coronary care unit opened the envelope to determine the treatment assignments. Therapy was begun with either 3 mg of captopril 3 times daily or 3 mg of captopril 3 times daily plus 5 mg of valsartan twice daily, within 36 h after admission. The doses of both drugs were gradually increased in a stepwise fashion, with the goal of reaching 40 mg of valsartan twice daily plus 25 mg of captopril 3 times daily in the combination group or 25 mg of captopril 3 times daily in the ACEI group within a 2-week period during initial hospitalization (Figure 1) . The investigators increased or decreased the doses of the study drugs at their discretion according to the patient's clinical status. The criteria for increasing the doses of the drugs included systolic blood pressure ≥100 mmHg (repeated measurements must be taken in the same position, ie, supine, sitting, or standing), absence of hypotension symptoms, serum potassium concentration <5.5 mEq/L, and serum creatinine concentration <1.2 mg/dl and ≤50% higher than the baseline concentration. 
IVUS
Procedure IVUS was performed in the acute phase (baseline) and at follow-up, using a 40-MHz mechanical scanning, monorail intracoronary ultrasound catheter (Boston Scientific, Natick, MA, USA). After i.c. isosorbide dinitrate 2-3 mg, the ultrasound catheter was positioned sufficiently distal to the PCI site. Pullback was performed automatically at 0.5 mm/s. IVUS was performed before any balloon inflation or stenting and after PCI. IVUS measurements were recorded on super VHS videotape for off-line analysis. In the acute phase, the results of IVUS after stent implantation (before final angiography) were analyzed.
Analysis IVUS measurements were obtained in accordance with the standards of the American College of Cardiology and European Society of Cardiology. 9 Each volume was assessed with volumetric analysis using echoPlaque 2 (Indec Systems, Santa Clara, CA, USA). Non-critical angiographic lesions were identified and co-registered with IVUS images. The target plaque had to be an intermediate lesion with ≤50% luminal narrowing on angiography and no previous PCI, and with a reproducible index side branch. Segments with marked calcification or tortuosity were avoided. All analyzed plaques were located in the treated vessel and had to be situated ≥10 mm from the culprit lesion. Each plaque was measured on conventional IVUS at 1-mm intervals throughout the most diseased (containing the greatest plaque volume) 10-mm segment. Segments with marked calcification or tortuosity were avoided. Baseline and follow-up IVUS images were reviewed side by side for measurement. Target segments were synchronized for baseline and follow-up IVUS by using at least 3 reproducible landmarks (calcium deposits, side branches, and/or other perivascular structures). Quantitative analysis, including target segment selection, was performed by an independent, experienced IVUS investigator who was blinded to the treatment assignments and the angiographic results. For IVUS analysis, volumetric analysis was performed if (1) there was no severe calcification that precluded accurate assessment of each volume; and (2) there was no marked tortuosity or artifact that negatively affected the results of analysis. The target lesion was measured at 1-mm intervals. The luminal/intimal borders were traced manually to determine the lumen cross-sectional area (CSA). The external elastic membrane (EEM) CSA, which represents the area encompassed by the medial/adventitial border, was measured by tracing the leading edge of the adventitia. Atheroma volume (AV) was calculated as the sum of the differences between the EEM and lumen CSAs across all 
Blood Sampling for Measurement of Neurohormone Levels
Serum samples for measurement of serum aldosterone levels were collected in the early morning after a 12-h fast while the patient was in a stable phase after randomization (a mean 14 days after randomization to minimize potential effects of AMI) 10,11 and at 7-month follow-up.
Definition of Major Adverse Coronary Events
Cardiac events, including death from cardiac causes, myocardial infarction (MI), or any revascularization (repeated PCI or coronary artery bypass grafting), were recorded. For the primary endpoint (nominal change in PAV), the smallest number of patients that could provide a 90% statistical power to detect a treatment-related difference of 3.0% with a standard deviation of 5.0% was calculated to be 120 in total at a 2-sided significance level of 5.0%. Given a dropout rate of 25%, 160 patients were required to be enrolled. A treatment-related difference of 3.0% and a standard deviation of 5.0% were assumed on the basis of a previous trial comparing moderate and intensive lipid-lowering therapies. 6 We used data for primary analysis if patients had measurable IVUS both at baseline and at follow-up. A safety analysis was based on the intension-to-treat principle including all randomized patients.
Statistical Analysis
Results
Patients
A total of 160 patients were randomly assigned to treatment, and 132 (83%) completed the study protocol. The ACEI group consisted of 69 participants, and the combination group, 63. IVUS images qualifying for evaluation both at baseline and at follow-up were obtained in 116 patients: 58 in the ACEI group and 58 in the combination group. The numbers of patients who were screened and randomized and the reasons for discontinuation are shown in Figure 2 . The target dose was achieved in 80% of the patients who received valsartan and captopril (mean dose, 72 mg valsartan daily, 68 mg captopril daily) and in 84% of those who received captopril (mean dose, 64 mg daily).
Baseline Characteristics
The baseline characteristics of patients included in the primary analysis are shown in Table 1 . PCI was successfully Abbreviations as in Table 2 . performed in all patients. The baseline characteristics of the patients in the 2 treatment arms were well matched, and there were no clinically significant differences in age, sex, incidence of coronary risk factors, peak creatine phosphokinase levels, or culprit artery between the treatment groups. There were also no significant differences between the groups in the use of oral medications other than study drug at discharge. No other anti-hypertensive drugs were added during the 7-months of follow-up. Table 1 also summarizes laboratory values and blood pressure at baseline and at follow-up. Average systolic and diastolic blood pressures at admission and at discharge were similar in the groups. Nevertheless, after 7 months of treatment, mean systolic blood pressure was lower in the combination group than in the ACEI group (117±17 mmHg vs. 125±16 mmHg; P=0.02), as was the plasma aldosterone level (56.0±30.3 pg/ml vs. 75.3±37.6 pg/ml P=0.02). Lipid profiles and high-sensitivity C-reactive protein levels were similar in the groups at baseline and at follow-up. The changes in high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein during the study did not differ between the treatment groups.
Laboratory Results and Blood Pressure
Efficacy Analysis
In the study group as a whole, there were trends toward plaque regression and lumen enlargement. The median change in AV was -2.0 mm 3 (95% confidence interval [CI]: -7.5 to 0.3 mm 3 ; P=0.06 as compared with baseline). The median change in EEM volume was -1.4 mm 3 (95%CI: -2.9 to 4.1 mm 3 ; P=0.73 as compared with baseline). The median change in LV was 1.6 mm 3 (95%CI: -0.2 to 8.4 mm 3 ; P=0.06 as compared with baseline). Plaques proximal to the sites of PCI were analyzed in 72% of the patients. Table 2 lists the results of volumetric IVUS analysis of target plaque at baseline and at 7-month followup. No volume parameter differed significantly between the groups at baseline or at follow-up. The nominal change in PAV, the primary efficacy measure, had a greater reduction in the combination group than in the ACEI group: -1.9% (95%CI: -4.5 to 0.87%) vs. -0.68% (95%CI: -2.4 to 1.2%). Although this difference did not reach statistical significance (P=0.06), there was a significant within-group decrease from baseline in the combination group (P<0.004) and no change in the ACEI group (P=0.18). The %ΔAV, a secondary efficacy measure, did not differ between the groups (P=0.59). In contrast, %ΔLV was significantly larger in the combination group: 4.3% (95%CI: -5.3 to 13.5%) vs. -0.3% (95%CI: -8.5 to 7.6%; between the groups, P=0.03).
Nominal Change in PAV and %ΔAV vs. Coronary Risk Factors
We analyzed the data according to the presence or absence of coronary risk factors and statin treatment ( Table 3 ). In the subgroup of patients without diabetes mellitus, nominal change in PAV induced by additional ARB therapy was greater than their counterparts (-0.3% vs. -2.4%, P=0.03), whereas no difference was observed in patients with diabetes mellitus (-0.8% vs. -1.7%, P=0.78). In the subgroup of patients with other coronary risk factors and statin treatment, no significant difference in the nominal change in PAV and %ΔAV was observed.
Logistic Regression Analysis of AV Progression
During follow-up, 51 patients had AV progression as determined by nominal change in PAV. Table 4 lists the result of simple and multiple regression analysis to examine the association between several variables including coronary risk factors and AV progression. Monocyte count at follow-up was associated with AV progression on simple regression analysis, but multiple logistic regression did not show any association.
Logistic Regression Analysis of LV Enlargement
During follow-up, 67 patients had LV enlargement. On simple logistic regression analysis, age, statin use at discharge, and ARB use at discharge were associated with LV enlargement. Changes of systolic blood pressure from baseline to follow-up, however, were not associated with LV enlargement (P=0.65). Multiple logistic regression analysis was performed to examine the potential independent effect of several variables on LV enlargement. Statin use at discharge (odds ratio [OR], 3.284; Table 4 . Effect of ARB on Coronary Atherosclerosis 95%CI: 1.046-10.311; P=0.02) and the combination of ARB and ACEI (OR, 2.144; 95%CI: 1.818-5.618; P=0.03) were independently associated with LV enlargement. Beta-blocker use at discharge (OR, 0.547; 95%CI: 0.204-0.991; P=0.04) were inversely associated with lumen enlargement ( Table 5) .
Adverse Events
There were no significant differences during 7-month followup in the prevalence of major cardiac events between the groups. Cardiac death and non-fatal MI did not occur during follow-up. Restenosis rate did not differ between the groups (14 patients in the combination group and 19 in the ACEI group; P=0.37). Target lesion revascularization for restenosis was performed in 10% (8/79) of the combination group and 14% (12/81) of the ACEI group (P=0.37). The study drugs were discontinued because of either adverse reactions or abnormality of laboratory data in 20% and 15% of the combination group and the ACEI group, respectively (P=0.37).
Discussion
In this study, combined treatment with an ARB and ACEI was associated with greater reductions in blood pressure and plasma aldosterone levels than was an ACEI alone in patients with AMI. Nonetheless, there was no significant difference in the progression of coronary atherosclerosis between the treatment groups. The percent change in LV (the secondary efficacy measure), however, was significantly greater in the combination group. To our knowledge, this is the first clinical IVUS study to compare the effects on non-culprit intermediate coronary atherosclerosis of combined treatment with an ARB and ACEI with those of an ACEI alone in patients with AMI.
In the present study, the combination of an ACEI and ARB was no more beneficial than an ACEI alone with respect to the progression of coronary atherosclerosis as assessed on IVUS after 7 months of treatment. The present findings are similar to those of the atherosclerosis substudy of the Quinapril Ischemic Events Trial (QUIET), which reported that an ACEI (quinapril 20 mg daily) had no discernible effect on coronary atherosclerosis as assessed on angiography. 12 In contrast, the study to Evaluate Carotid Ultrasound Changes in patients Treated with Ramipril and Vitamin E (SECURE) substudy demonstrated that long-term therapy with an ACEI (ramipril 2.5 or 10 mg daily) retards the progression of human atherosclerosis. 13 The Valsartan in Acute Myocardial Infarction (VALIANT) trial and Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET), which were designed to investigate additional cardiovascular protecting effects of ACEI plus ARB, failed to show any reduction in cardiovascular events, including death, MI, and stroke, as compared with ACEI alone. 3, 4 The absence of a decrease in plaque in the combination group as compared with the ACEI group in the present study is in accordance with the results of these pivotal clinical trials, although whether coronary plaque progression is directly related to outcomes remains to be determined.
Several reasons may account for the lack of an effect of ARB treatment on coronary plaque progression in the present study. First, even though combination therapy produced a more complete inhibition of RAS (as suggested by the greater lowering of blood pressure and plasma aldosterone levels), RAS inhibition with an ACEI alone may be sufficient, and dual blockade might not confer any additional benefits in terms of reducing the progression of coronary atherosclerosis. Second, it is noteworthy that the nominal change in PAV indicated no progression in the ACEI group and suggested even regression in the combination group. This result may be ascribed to the successful treatment of patients with other drugs, including statins, during the study. Consequently, further clinical benefits afforded by additional treatment with multiple drugs that block the RAS were therefore not possible or perhaps not discernible. Especially in the Japanese population, statins have been reported to suppress the progression or induce the regression of coronary atherosclerosis even in patients with relatively high target low-density lipoprotein cholesterol levels. 14 It is also possible that the effect of combination therapy is different in some subgroups of patients. The impact of combination therapy was more enhanced in patients without diabetes mellitus ( Table 3) . This finding is consistent with the subanalysis of JAPAN-ACS trial, which found that the impact of aggressive lipid-lowering therapy was more prominent in patients without diabetes mellitus. 15 Third, we cannot exclude the possibility that ARB induced a change in the histologic composition of plaque, which was not assessed in this study. Potential clinical benefits of combination therapy may be reflected in plaque stability rather than in absolute plaque volume. In several previous pivotal studies, the target dose of captopril was 50 mg t.i.d. and valsartan 160 mg b.i.d. Thus, the target doses in the present study seem somewhat low as compared with those used in previous studies. Therefore, it is possible that the present study may have underestimated the beneficial effects of ACEI. The doses of all antihypertensive drugs, however, were in accordance with the guidelines of the Japanese Hypertension Society. 16 The mean doses of valsartan (72 mg) and captopril (68 mg) used in the present study were equivalent to 0.9-fold the respective upper limits of the approved doses in Japan. Therefore, we believe that the doses of these antihypertensive drugs were appropriate. Moreover, studies in Japanese hypertensive patients have shown that the addition of valsartan at a dose of 75-85 mg, similar to the level used in the present study, to conventional treatment prevents stroke, transient ischemic attack, angina pectoris, and heart failure. 17, 18 A recent Japanese study demonstrated that a half-dose combination of ACEI and ARB might suppress left ventricular remodeling in patients with AMI without an increase in adverse events. 19 We observed significant lumen enlargement without plaque progression during additional ARB treatment, which was independent of blood pressure. This suggests that combined inhibition of RAS altered the coronary arterial dilator response to isosorbide dinitrate. Reduction of the nominal change in PAV in the combination group may also represent the improvement of vessel tone, because no change in the %ΔAV from baseline to follow up was observed. Disturbances in vasomotor tone are closely linked to the development of early atherosclerosis and play an integral part in the pathophysiology of myocardial ischemia. A previous study demonstrated that a blunted vasodilator response to nitroglycerin was a significant independent predictor of poor long-term outcome, suggesting that endothelium-independent vasodilator capacity also has an important role in atherosclerotic disease progression. 20 The present study also showed that statin use at discharge was associated with lumen enlargement during followup. In contrast, β-blocker use at discharge was associated with lumen constriction. The present results are consistent with those of a previous study demonstrating that coronary vasomotor function is increased by statin treatment. 21 In addition, β-blockers can induce coronary spasms by converting the effect of a sympathetic stimulus into a pure α-adrenergic vasoconstrictor response. 22 YANO H et al.
Lower plasma aldosterone levels at follow-up in the combination group may partly explain lumen enlargement. Several studies suggest that aldosterone may act not only on the endothelium of blood vessels, but also on the smooth muscle layer as well as the perivascular adventitial layer. Duprez et al found an association between the prevailing level of aldosterone and reduced artery compliance in patients with heart failure and suggested that aldosterone may act on the smooth muscle layer. 23 Experimental evidence that aldosterone acts on the perivascular adventitia comes from a study in rats showing that aldosterone can increase perivascular fibrosis around coronary arteries and that spironolactone can reverse it. 24 Thus, aldosterone may have harmful effects on all 3 layers of vascular tissue. In the present study, decreased levels of aldosterone in the combination group may have improved coronary artery compliance and prevented fibrosis of the coronary perivascular adventitia, leading to lumen enlargement. Taken together, lumen enlargement may have resulted from an improvement in coronary vascular tone or a change in the histologic composition of plaque. But we cannot differentiate acute vasodilator effects due to the study drug, which might not persist after drug withdrawal, from a beneficial structural effect on lumen enlargement.
Study Limitations
This study had several limitations. First, the present study was done in a single center and the number of patients was low. The median follow-up of 7 months might have been too short to evaluate the effects of treatment on coronary plaque progression. Thus, the study may have been underpowered to detect effects on plaque progression. A previous study, however, demonstrated significant plaque volume regression within 6 months in Japanese patients with acute coronary syndrome who received aggressive lipid-lowering therapy, 25 indicating that a relatively short period might be adequate to evaluate coronary plaque behavior in patients with acute coronary syndrome. Second, this study was not placebo-controlled, because current guidelines and practice patterns require ACEI treatment for high-risk patients with AMI, and random assignment of patients to placebo was deemed ethically unacceptable. Third, because %ΔLV was the secondary endpoint, the present results should be considered as hypothesis generating rather than definitive. Furthermore, the higher dropout rate in the combination group may have biased the results. Finally, we randomized patients by the sealed envelope method. Therefore, the possibility of selection bias cannot be completely excluded.
Conclusions
Combined treatment with an ARB and ACEI had minimal effects on coronary plaque progression in patients with AMI as compared with ACEI monotherapy. Combined therapy with these 2 drugs, however, induced lumen enlargement.
